Ligand Pharmaceuticals (LGND)
(Delayed Data from NSDQ)
$70.57 USD
+0.20 (0.28%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $70.64 +0.07 (0.10%) 7:58 PM ET
1-Strong Buy of 5 1
D Value D Growth B Momentum D VGM
Company Summary
San Diego, CA-based Ligand is a biotechnology company whose business model is based on developing or acquiring royalty revenue-generating assets. The company is focused on the development and licensing of biopharmaceutical assets.
Ligand’s Captisol formulation technology has allowed it to enter several licensing deals and generate royalties. Captisol is a well-validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. The Captisol drug formulation platform technology was added to Ligand’s technology portfolio following its 2011 ...
Company Summary
San Diego, CA-based Ligand is a biotechnology company whose business model is based on developing or acquiring royalty revenue-generating assets. The company is focused on the development and licensing of biopharmaceutical assets.
Ligand’s Captisol formulation technology has allowed it to enter several licensing deals and generate royalties. Captisol is a well-validated chemically modified cyclodextrin that is designed to improve safety and solubility, stability, and bioavailability or lessen the volatility, irritation, smell or taste of drugs. The Captisol drug formulation platform technology was added to Ligand’s technology portfolio following its 2011 merger with CyDex.
In September 2023, Ligand signed an agreement to merge its subsidiary Pelican Technology Holdings, Inc., with Primordial Genetics to create a new stand-alone private company focused on synthetic biology called Primrose Bio. The company owns a 49.9% stake in this entity and continues to retain all existing commercial royalties related to Pelican Expression technology.
The company’s proprietary technologies also consist of prodrug technologies platforms, such as HepDirect and LTP platforms. The company continues to buy smaller companies to increase its technology platforms.
In January 2024, the FDA approved Zelsuvmi (berdazimer gel), currently the only topical treatment gel for molluscum contagiosum (molluscum) in individuals aged one year and older. This product was added to Ligand’s portfolio after it added certain of Novan’s assets in 2023 for $12.2 million.
Ligand has partnership agreements with leading healthcare companies like Novartis, Amgen, Merck, Pfizer, Gilead and Lilly.
In November 2022, the company completed the separation of its OmniAb business into a separate public company named OmniAb. The spun-off OmniAb was listed on the Nasdaq Global Markets under the ticker symbol OABI w.e.f. Nov 2, 2022.
In 2023, Ligand recognized total revenues of $131.3 million, down 33% year over year. The company derived around 21.6% of its revenues from Captisol sales. Royalties contributed about 63.9% to total revenues, while Contract revenues contributed 14.5% in 2023.
General Information
Ligand Pharmaceuticals Incorporated
555 HERITAGE DRIVE SUITE 200
JUPITER, FL 33458
Phone: 858-550-7500
Fax: 858-550-1826
Email: investors@ligand.com
Industry | Medical - Biomedical and Genetics |
Sector | Medical |
Fiscal Year End | December |
Last Reported Quarter | 3/31/2024 |
Earnings Date | 5/7/2024 |
EPS Information
Current Quarter EPS Consensus Estimate | 1.13 |
Current Year EPS Consensus Estimate | 4.56 |
Estimated Long-Term EPS Growth Rate | NA |
Earnings Date | 5/7/2024 |
Price and Volume Information
Zacks Rank | |
Yesterday's Close | 70.37 |
52 Week High | 94.57 |
52 Week Low | 49.24 |
Beta | 1.01 |
20 Day Moving Average | 158,475.16 |
Target Price Consensus | 116.33 |
4 Week | -3.46 |
12 Week | -5.33 |
YTD | -1.19 |
4 Week | -0.54 |
12 Week | -7.95 |
YTD | -7.59 |
Shares Outstanding (millions) | 17.70 |
Market Capitalization (millions) | 1,249.46 |
Short Ratio | NA |
Last Split Date | 11/19/2010 |
Dividend Yield | 0.00% |
Annual Dividend | $0.00 |
Payout Ratio | 0.00 |
Change in Payout Ratio | 0.00 |
Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
P/E (F1) | 15.48 |
Trailing 12 Months | 12.23 |
PEG Ratio | NA |
vs. Previous Year | 403.85% |
vs. Previous Quarter | 11.27% |
vs. Previous Year | -44.22% |
vs. Previous Quarter | -14.50% |
Price/Book | 1.75 |
Price/Cash Flow | 14.11 |
Price / Sales | 9.51 |
3/31/24 | NA |
12/31/23 | 11.98 |
9/30/23 | 9.67 |
3/31/24 | NA |
12/31/23 | 10.27 |
9/30/23 | 8.03 |
3/31/24 | NA |
12/31/23 | 14.15 |
9/30/23 | 16.15 |
3/31/24 | NA |
12/31/23 | 12.72 |
9/30/23 | 14.54 |
3/31/24 | NA |
12/31/23 | 61.10 |
9/30/23 | 40.54 |
3/31/24 | NA |
12/31/23 | 37.80 |
9/30/23 | 9.09 |
3/31/24 | NA |
12/31/23 | 48.48 |
9/30/23 | 46.03 |
3/31/24 | NA |
12/31/23 | 40.39 |
9/30/23 | 38.48 |
3/31/24 | NA |
12/31/23 | 0.47 |
9/30/23 | 1.53 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |
3/31/24 | NA |
12/31/23 | 0.00 |
9/30/23 | 0.00 |